Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rethinking Oncology Development: Master Protocols May Shorten Time To Approval

This article was originally published in RPM Report

Executive Summary

Master protocols that allow for the simultaneous study of multiple agents will shave more time off in the clinic than one-off studies in small groups of patients, FDA’s Janet Woodcock predicted. The current timeframes in oncology development are “unacceptable,” and can be shortened, she said, by “doing things differently.”


Related Content

Master Protocols Are Both Welcome And Inevitable – US FDA's Woodcock
Genentech Wants Other Firms' Compounds For Mass Pediatric Cancer Screening
I-SPY 2 Helping To Normalize Adaptive Trial Designs
Clinical Trial Success Rates Still Dismal, But Certain Sectors Outperform
Changing the Subject: The “All-Cancer Trial”
Changing the Subject (Part 3): The “All-Cancer Trial”
Lung Cancer “Master Protocol” Eyed As Paradigm-Changing Approach To Drug Development
Co-Development Guidance Gives More Attention To IND, NDA/BLA Submissions
Biomarkers Consortium Launches Adaptive Trial To Test Targeted Breast Cancer Drugs


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts